The wide range of people with CKD randomized into EMPA-KIDNEY included groups excluded from or under-represented in the other SGLT-2 inhibitor trials with a primary focus on kidney disease progression [18, 23–25]. Here, SLC5A2 is linked to chronic kidney disease.